A Comparative Study of Intravenous Injection Form and Oral Jelly Form of Alendronate Sodium Hydrate for Bone Mineral Disorder after Gastrectomy

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background/Aims: Osteoporosis is found to have high prevalence after gastrectomy and therefore, it is important to prevent this condition by means of effective medication, such as alendronate sodium hydrate. Methods: A total number of 48 gastric cancer patients diagnosed with osteoporosis after R0 gastrectomy was registered in this study between December 2013 and August 2014. Twenty-three patients received intravenous (i.v.) alendronate sodium hydrate and 25 patients received the drug in an oral jelly form. Serological and urinary examinations related to bone metabolism and bone mineral density (BMD) were performed periodically and the results obtained from the 2 groups were compared. Results: BMD increased, serum levels of bone-specific alkaline phosphatase and tartrate-resistant acid phosphatase-5b, and the urine level of urine N-terminal telopeptide decreased with time in both groups. However, the serum Ca level did not change. Two-way analysis of variance revealed no significant differences in these factors between the 2 groups. Conclusion: It is essential to prevent both forms of osteoporosis by using alendronate sodium hydrate after gastrectomy for gastric cancer. A prospective, randomized, controlled trial in many patients following long duration should be conducted to clarify the benefits of i.v. alendronate sodium hydrate.

Related collections

Author and article information

Journal

Journal ID (publisher-id): DIG

Journal ID (nlm-ta): Digestion

Journal ID (doi): 10.1159/issn.0012-2823

Title: Digestion

Publisher: S. Karger AG

ISSN (Print): 0012-2823

ISSN (Electronic): 1421-9867

Publication date Subscription-year: 2017

Publication date (Print): March 2017

Publication date (Electronic): 18 February 2017

Volume: 95

Issue: 2

Pages: 162-171

Affiliations

^aDepartment of Surgery, Gastroenterological Center, and ^bDepartment of Gastroenterological Surgery, and ^cDepartment of Clinical Statistics, Graduate School of Medicine, Yokohama City University, Yokohama, Japan

Author notes

*Chikara Kunisaki, MD, PhD, Department of Surgery, Gastroenterological Center, Yokohama City University, 4-57 Urafne-cho, Minami-ku, Yokohama 232-0024 (Japan), E-Mail s0714@med.yokohama-cu.ac.jp

Article

Publisher ID: 458755 Other ID: Digestion 2017;95:162-171

DOI: 10.1159/000458755

PubMed ID: 28214864

SO-VID: 1d3a54a9-4253-4899-ac98-1cd87722975f

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

History

Date received : 18 October 2016

Date accepted : 02 February 2017

Page count

Figures: 5, Tables: 2, References: 31, Pages: 10

Comments

Comment on this article

scite_

Cited by 3

See all cited by

- Version 1

Call for Papers: Artificial Intelligence in Gastroenterology

Submit here before September 30, 2024